Medical artificial intelligence (AI) company Lunit announced on May 22 that it will present the results of five studies utilizing its AI biomarker platform, Lunit Scope, at the 2026 American Society of Clinical Oncology (ASCO 2026) conference to be held in Chicago, USA, from May 29 to June 2.


Lunit to Present Five AI Biomarker Studies at ASCO 2026 View original image

Lunit has previously presented multiple studies based on Lunit Scope IO for predicting responses to immunotherapy at cancer conferences. At this year’s meeting, the company will showcase several studies utilizing immunohistochemistry (IHC)-based biomarker analysis models, including Lunit Scope HER2 and Lunit Scope uIHC.


One of the main studies involves biomarker analysis participation in a clinical trial led by Professor Lee Choongkeun's team at Yonsei University College of Medicine, targeting patients with HER2-positive advanced biliary tract cancer. This clinical trial evaluated a first-line treatment that combined the HER2-targeted therapy Herceptin (trastuzumab) and the immunotherapy Opdivo (nivolumab) with chemotherapy (gemcitabine + cisplatin). Lunit analyzed HER2 expression patterns and immune phenotypes (IP) using whole slide image (WSI) analysis with Lunit Scope HER2 and Lunit Scope IO.


The objective response rate (ORR) for all patients was 55%. Among patients whose IHC 3+ HER2-overexpressing cell ratio was at least 10%, the ORR was 80%, compared to 36.4% in the non-overexpressing group—a more than twofold difference. Additionally, 75% of immune-active patients, as identified by AI, responded to treatment. According to the company, this study demonstrates that AI-based quantitative analysis of HER2 expression can help distinguish responders to first-line combination therapy in HER2-positive biliary tract cancer.


Lunit will also disclose research analyzing tumor microenvironment (TME) characteristics in HER2-overexpressing non-small cell lung cancer (NSCLC). The company analyzed 2,054 H&E slide images with Lunit Scope IO and quantified the HER2 IHC 3+ tumor cell ratio in 1,099 cases that also had HER2 IHC slides using Lunit Scope HER2. The results showed that HER2 IHC 3+ tumors had a lower immune-active ratio—10.2% compared to 22.1%—than non-overexpressing tumors. This research confirmed that HER2-overexpressing NSCLC patients have an immune-inactive phenotype and that the Lunit Scope product line can precisely analyze IHC-based target protein expression and tumor microenvironment characteristics.


The company will additionally release research on tumor microenvironment analysis using Lunit Scope IO. In a rare cancer study on adenoid cystic carcinoma (ACC) conducted with Seoul National University Hospital, H&E slide images from 27 patients treated with the targeted therapy Inlyta (axitinib) were analyzed using Lunit Scope IO. Patients with high densities of both endothelial cells and tumor-infiltrating lymphocytes (TIL) within tumor stroma demonstrated longer progression-free survival (PFS) and overall survival (OS), once again demonstrating that AI-based tumor microenvironment analysis can be used to identify responders even in rare cancers.


In a study with Asan Medical Center on microsatellite stable (MSS) metastatic colorectal cancer, 51 H&E slide images from patients treated with immunotherapy were analyzed using Lunit Scope IO. Patients with a larger tertiary lymphoid structure (TLS) area showed longer PFS and OS. These results demonstrate that AI can be used to identify responders to treatment even in MSS colorectal cancer, which is generally known to have low response to immunotherapy.



Beomseok Seo, CEO of Lunit, stated, "At this year’s ASCO 2026, we are presenting numerous biomarker studies utilizing the Lunit Scope IHC analysis product line, thereby further expanding its range of applications. We will continue to strive for Lunit Scope to become the leading global platform that provides evidence for decision-making in drug development, clinical trial design, and patient selection."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing